BioTelemetry (BEAT) Tops Q1 EPS by 2c; Withdraws Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
BioTelemetry, Inc. Reports First Quarter 2020 Financial Results
May 6, 2020 4:05 PM EDTMALVERN, Pa., May 06, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ: BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the quarter ended March 31, 2020.
Quarter Highlights
Recognized quarterly revenue of $113.0 millionReached 8.7% year-over-year quarterly revenue growthAchieved 31st consecutive quarter of year-over-year revenue growthReported quarterly GAAP net income of $7.1 million, or 6.3% of revenueRealized quarterly adjusted EBITDA of $29.5 million, or 26.1% of revenue... More